OKYO Pharma will participate in the BTIG Biotechnology Conference 2026 for discussions on its therapies for eye diseases.
Quiver AI Summary
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and anterior segment eye diseases, has announced its participation in the BTIG Biotechnology Conference 2026, which will be held virtually on July 28-29, 2026. Key executives including CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli MD, PhD, will represent the company. In addition, OKYO plans to initiate a global Phase 3 clinical trial soon, aiming to enroll approximately 111 patients for assessing the effectiveness of a single-dose regimen of urcosimod in treating neuropathic corneal pain. For more details, interested parties are encouraged to visit their website or contact their business development team.
Potential Positives
- OKYO Pharma's participation in the BTIG Biotechnology Conference 2026 highlights its engagement with the investment community, potentially attracting interest and investment.
- The announcement of a planned global Phase 3 pivotal clinical trial for urcosimod signifies progress in its drug development pipeline, which may support the company's growth and market presence.
- The involvement of high-level executives in the conference reinforces the company’s commitment to transparency and communication with investors and stakeholders.
Potential Negatives
- Participation in a biotechnology conference may indicate a need for increased visibility and investor interest, suggesting potential challenges in garnering attention for their therapies.
- The announcement of a global Phase 3 pivotal clinical trial with only 111 patients may raise concerns about the robustness and generalizability of the trial results.
- The ongoing focus on neuropathic corneal pain (NCP) and anterior segment eye diseases could reflect a narrow therapeutic focus, potentially limiting the company's growth and diversification opportunities.
FAQ
What is the purpose of OKYO Pharma's participation in the BTIG Biotechnology Conference 2026?
OKYO Pharma is participating to discuss its investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
When is the BTIG Biotechnology Conference 2026 taking place?
The conference is scheduled for July 28-29, 2026.
Who from OKYO Pharma will be presenting at the conference?
Presenters include Robert J. Dempsey, Keeren Shah, and Flavio Mantelli MD, PhD.
What key clinical trial is OKYO Pharma planning to initiate?
OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial for urcosimod to treat neuropathic corneal pain.
How can investors schedule a meeting with OKYO Pharma management?
Investors can schedule a one-on-one meeting by contacting their BTIG representative.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OKYO Hedge Fund Activity
We have seen 6 institutional investors add shares of $OKYO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 3,652,190 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,880,025
- MAVEN SECURITIES LTD added 1,175,535 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,892,611
- STONEPINE CAPITAL MANAGEMENT, LLC added 850,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,368,500
- BALYASNY ASSET MANAGEMENT L.P. added 584,796 shares (+inf%) to their portfolio in Q1 2026, for an estimated $941,521
- DAUNTLESS INVESTMENT GROUP, LLC removed 467,704 shares (-99.2%) from their portfolio in Q1 2026, for an estimated $753,003
- RENAISSANCE TECHNOLOGIES LLC removed 138,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $222,180
- UBS GROUP AG added 57,588 shares (+2651.4%) to their portfolio in Q1 2026, for an estimated $92,716
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OKYO Analyst Ratings
Wall Street analysts have issued reports on $OKYO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/20/2026
To track analyst ratings and price targets for $OKYO, check out Quiver Quantitative's $OKYO forecast page.
Full Release
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.
Company Participation : Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer
Date/Time: July 28-29, 2026
Location: Virtual
1:1 Meetings : schedule a one-on-one meeting with management by contacting your BTIG representative
About OKYO
Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visit www.okyopharma.com .
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email:
[email protected]
